Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Cell Commun Signal ; 22(1): 457, 2024 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-39327578

RESUMO

Microglial activation-mediated neuroinflammation is a major contributor to neuronal damage after cerebral ischemia. The Fractalkine (FKN)/CX3C chemokine receptor 1 (CX3CR1) axis plays a critical role in regulating microglial activation and neuroinflammation. The aim of this study is to ascertain the role and mechanism of FKN/CX3CR1 axis in hypoxic postconditioning (HPC)-induced anti-inflammatory and neuroprotective effects on transient global cerebral ischemia (tGCI). We found that HPC suppressed microglial activation and alleviated neuroinflammation in hippocampal CA1 after tGCI. Meanwhile, HPC upregulated the expression of FKN and CX3CR1 in neurons, but it downregulated the expression of CX3CR1 in glial cells after tGCI. In addition, the overexpression of FKN induced by the administration of FKN-carried lentivirus reduced microglial activation and inhibited neuroinflammation in CA1 after tGCI. Furthermore, silencing CX3CR1 with CX3CRi-carried lentivirus in CA1 after tGCI suppressed microglial activation and neuroinflammation and exerted neuroprotective effects. Finally, the overexpression of FKN caused a marked increase of neuronal CX3CR1 receptors, upregulated the phosphorylation of Akt, and reduced neuronal loss of rats in CA1 after tGCI. These findings demonstrated that HPC protected against neuronal damage in CA1 of tGCI rats through inhibiting microglial activation and activating Akt signaling pathway via FKN/CX3CR1 axis.


Assuntos
Receptor 1 de Quimiocina CX3C , Quimiocina CX3CL1 , Microglia , Neuroproteção , Animais , Masculino , Ratos , Isquemia Encefálica/metabolismo , Isquemia Encefálica/patologia , Isquemia Encefálica/genética , Região CA1 Hipocampal/metabolismo , Região CA1 Hipocampal/patologia , Quimiocina CX3CL1/metabolismo , Quimiocina CX3CL1/genética , Receptor 1 de Quimiocina CX3C/metabolismo , Receptor 1 de Quimiocina CX3C/genética , Pós-Condicionamento Isquêmico , Microglia/metabolismo , Microglia/patologia , Neurônios/metabolismo , Neurônios/patologia , Ratos Sprague-Dawley , Transdução de Sinais
2.
J Neuropathol Exp Neurol ; 75(9): 816-26, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27371711

RESUMO

Secondary degeneration in areas beyond ischemic foci can inhibit poststroke recovery. The cysteine protease Cathepsin B (CathB) regulates cell death and intracellular protein catabolism. To investigate the roles of CathB in the development of secondary degeneration in the ventroposterior nucleus (VPN) of the ipsilateral thalamus after focal cerebral infarction, infarct volumes, immunohistochemistry and immunofluorescence, and Western blotting analyses were conducted in a distal middle cerebral artery occlusion (dMCAO) stroke model in adult rats. We observed marked neuron loss and gliosis in the ipsilateral thalamus after dMCAO, and the expression of CathB and cleaved caspase-3 in the VPN was significantly upregulated; glial cells were the major source of CathB. Although it had no effect on infarct volume, delayed intracerebroventricular treatment with the membrane-permeable CathB inhibitor CA-074Me suppressed the expression of CathB and cleaved caspase-3 in ipsilateral VPN and accordingly alleviated the secondary degeneration. These data indicate that CathB mediates a novel mechanism of secondary degeneration in the VPN of the ipsilateral thalamus after focal cortical infarction and suggest that CathB might be a therapeutic target for the prevention of secondary degeneration in patients after stroke.


Assuntos
Catepsina B/antagonistas & inibidores , Catepsina B/metabolismo , Infarto Cerebral/metabolismo , Dipeptídeos/farmacologia , Tálamo/metabolismo , Fatores Etários , Animais , Infarto Cerebral/tratamento farmacológico , Infarto Cerebral/patologia , Dipeptídeos/uso terapêutico , Masculino , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Tálamo/efeitos dos fármacos , Tálamo/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA